• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

01.11.2018

Teva Reports Third Quarter 2018 Financial Results

Revenues of $4.5 billion Free cash flow of $704 million GAAP diluted loss per share of $0.27 Non-GAAP diluted EPS of $0.68 Spend base reduction of $1.8 billion in the first nine months of 2018; on-track to achieve $3.0 billion by the end of 2019 AJOVY™ (fremanezumab) was approved by the FDA in September 2018 and immediately launched Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.80-2.95 from $2.55-2.80 Free cash flow guidance raised ...
21.10.2018

Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel

PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 21, 2018-- Teva Pharmaceuticals announced that Teva executives Kåre Schultz and Brendan O’Grady, alongside State of New Jersey Governor, Phil Murphy, formalized Teva’s commitment to consolidate its North America Commercial business areas into New Jersey (NJ) today at the company’s global headquarters in Petach Tikva, Israel. Announced earlier this year as part of a global restructuring process, Teva will establish its North America headquarters in Parsippany-Troy Hills, including more than 1,000 high-wage jobs and the transfer and creation of more than 800 positions. Teva accepted a...
11.10.2018

Teva Draws on Patient Experience to Empower Those Living with Chronic Conditions

Patient-centric website ‘Life Effects’ European launch sees expanded content featuring insights from European patients with chronic conditions AMSTERDAM--(BUSINESS WIRE)--Oct. 11, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) Congress in Berlin. This online content initiative was created following extensive research from 13,500 patients globally and is now being launch...
10.10.2018

Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar

If approved, CT-P10, a proposed biosimilar to Rituxan® (rituximab), will be the first rituximab biosimilar to be approved in the United States SILVER SPRING, Md. & JERUSALEM--(BUSINESS WIRE)--Oct. 10, 2018-- Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan®1 (rituximab) for the treatment of adult patients in three proposed indications. The proposed indications are: (1) re...
10.10.2018

Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE® (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis

Safety results from the open-label extension study of the original U.S. COPAXONE® pivotal trial presented at the 2018 ECTRIMS Annual Meeting in Berlin JERUSALEM--(BUSINESS WIRE)--Oct. 10, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced safety and tolerability results representing 25 years of data from the open-label extension study of the original U.S. pivotal trial of COPAXONE® (glatiramer acetate injection) for the treatment of relapsing forms of multiple sclerosis (RMS). The extension study initially examined the safety of COPAXONE® 20 mg/mL daily and then also the 40 mg/mL three tim...
08.10.2018

Teva to Present New Data at 34th European Committee for Treatment and Research in Multiple Sclerosis Congress in Berlin

JERUSALEM--(BUSINESS WIRE)--Oct. 8, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on COPAXONE® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (RMS), will be presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, October 10-12, 2018. “We are honored to contribute data spanning more than 25 years of research on COPAXONE® at this year’s ECTRIMS Congress,” Danny McBryan, M.D., Senior Vice President of Global Medical Affairs and Pharmacovigilance at Teva. “Teva’s C...
05.10.2018

Teva to Report Third Quarter 2018 Financial Results on November 1, 2018

JERUSALEM--(BUSINESS WIRE)--Oct. 5, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its third quarter 2018 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States ...
27.09.2018

Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis® in the United States

JERUSALEM--(BUSINESS WIRE)--Sep. 27, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis®1 (tadalafil) tablets (2.5 mg, 5 mg, 10 mg, 20 mg) in the U.S. Tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and symptoms of BPH (ED/BPH). Teva’s EVP and Head of Global R&D, Hafrun Fridriksdottir said, “We’re proud to offer an affordable treatment option for the estim...
18.09.2018

Teva Announces Early Results of Debt Tender Offer and Election of Early Settlement

JERUSALEM--(BUSINESS WIRE)--Sep. 18, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $400 million (the “Maximum Amount”) a portion of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 1.700% Senior Notes due 2019, CUSIP 88167A AB7 / ISIN US88167AAB70, issued by Teva Pharmaceutical Finance Netherlands III B.V. (the “Priority 1 No...
15.09.2018

Teva Announces U.S. Approval of AJOVY™ (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults

JERUSALEM--(BUSINESS WIRE)--Sep. 14, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly (675 mg) and monthly (225 mg) dosing options. This press release features multimedia. View the full release here: https://www.businesswir...